Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Ependymoma × Carboplatin × Clear all

Phase

Phase 2 4 Phase 1 3 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 12 Triple Negative Breast Neoplasms 6 Breast Neoplasms 6 Lung Neoplasms 5 Urinary Bladder Neoplasms 4 Ovarian Neoplasms 4 Endometrial Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Medulloblastoma 2 Fallopian Tube Neoplasms 2 Brain Neoplasms 2 Waldenstrom Macroglobulinemia 1 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Thymic epithelial tumor 1 Thrombocythemia, Essential 1 Squamous NSCLC 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Retinoblastoma 1 Recurrence 1 Primary Myelofibrosis 1 Primary Malignant Neoplasm of Ovary 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1

Interventions

trofosfamide 1 Thiotepa 1 Temozolomide 1 Etoposide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00749723 2018-07-20

HIT-REZ-2005

University Hospital, Bonn

Phase 2/3 Completed

Brain Neoplasms, Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡